Buy & Sell Smith & Nephew plc (SNN) – Smith & Nephew plc Price Today
Aura AI Summary
Key Stats
- $13.01BMarket Cap
- HealthSector
- -21.14%3M Drawdown
- $15.78BEnterprise Value
- 2.56%Dividend Yield
- 116 daysTypical Hold Time
Smith & Nephew plc (SNN) is currently valued at a market capitalization of $13.01B, with an enterprise value of $15.78B. Over the past 52 weeks, Smith & Nephew plc has traded between a low of $28.58 and a high of $38.7, highlighting its annual price range. Over the past three months, Smith & Nephew plc has recorded a drawdown of -21.14%, reflecting recent price volatility. Smith & Nephew plc offers a dividend yield of 2.56%, with the most recent dividend of $0.48 paid on 27 Mar 26. On average, investors hold Smith & Nephew plc for approximately 116 days, indicating typical investor behavior on the platform.
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Most Recent News
CBAK Energy unveils advanced LFP cylindrical batteries boosting Southeast Asia's electric mobility.
CBAK Energy Technology showcased its innovative lithium-ion and sodium-ion cylindrical batteries designed for Southeast Asia's electric two- and three-wheelers at Autotech & Accessories 2026. Their batteries feature long life, high reliability, and s...

WeRide and Renault deploy autonomous Robobus at Roland-Garros for third year, expanding night service.
WeRide and Renault Group continue their partnership by operating the autonomous Robobus shuttle service at the Roland-Garros tennis tournament for the third consecutive year. The service runs a 2.8 km route connecting key points around the stadium, o...

Eli Lilly's gene therapy VERVE-102 cuts LDL cholesterol by up to 62% with lasting effects.
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
